Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats

Journal of Hypertension

Volumn 17, Issue 1, 1999, Pages 53-60

  Naruse, Mitsuhide ^a   Tanabe, Akiyo ^a   Seki, Toshirou ^a   Adachi, Chika ^a   Yoshimoto, Takanobu ^a   Mishina, Naoko ^a   Imaki, Toshihiro ^a   Naruse, Kiyoko ^a   Demura, Reiko ^a   Demura, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Calcium blocker; Cardiovascular tissue; Endothelial type nitric oxide synthase; Endothelin 1; Stroke prone spontaneously hypertensive rats

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; MESSENGER RNA; NIFEDIPINE; NILVADIPINE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; BIOPSY; BRAIN TISSUE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; HEART; KIDNEY; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEASE PROTECTION ASSAY; SOUTHERN BLOTTING; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

EID: 0032976441     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917010-00009     Document Type: Article

References (49)

1. Dahlöf B, Pennert K, Hansson L. Reversal of ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5:95-110.
2. Ohotsuka M, Sakai S, Miura S, Kurosaki M, Koibuchi Y, Ono T, et al. Effects of nilvadipine, a new calcium entry blocker, on systemic blood pressure, cardiac hypertrophy and venous distensibility in spontaneously hypertensive rats. Arch Int Pharmacol Ther 1989; 301:228-245.
3. Shigematsu S, Hiramatsu K, Aizawa T, Yamada T, Takasu N, Niwa A, et al. Regression of left ventricular hypertrophy in patients with essential hypertension: outcome of 12 years antihypertensive treatment. Cardiology 1990; 77:280-286.
4. Nagano N, Iwatsubo H, Hata T, Mikami H, Ogihara T. Effects of antihypertensive treatment on cardiac hypertrophy and function in elderly hypertensive patients. 1991; 17 (Suppl 2):s163-s165.
5. Ferrante F, Bronzetti E, Ciriaco E, Felici L, Amenta F. Effects of nicardipine treatment upon cardiac hypertrophy in spontaneously hypertensive rats: a morphometric and ultrastructural study. J Hypertens 1992; 10:507-512.
6. Natsume T. Therapeutic advances in the treatment of left ventricular hypertrophy. Eur Heart J 1993; 14 (Suppl D):33-37.
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by endothelial cells. Nature 1988; 332:411-415.
8. Palmer RMJ, Ferrigo AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
9. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 60:82-92.
10. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activalable component of the inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM (editor): Mechanisms of vasodilatation. New York: Raven Press; 1988. pp. 401-419.
11. Inagami T, Naruse M, Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol 1995; 57:171-189.
12. Naruse M, Naruse K, Demura H. Recent advances in endothelin research on cardiovascular and endocrine systems. Endocrine J 1994; 41:491-507.
13. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109-142.
14. Forstermann U, Closs El, Pollock JS, Nakane M, Schwarz P, Gath I, et al. Nitric oxide synthase isozymes characterization, purification, molecular cloning, and functions. Hypertension 1994; 23:1121-1131.
15. Furuta T, Shibata S, Kodama I, Yamada K. Cardiovascular effects of FR34235, a new dihydropyridine slow channel blocker, in isolated rabbit myocardium and aorta. J Cardiovasc Pharmacol 1983; 5:836-841.
16. Ohotsuka M, Ono T, Hiroi J, Esumi K, Kumada S. Comparison of the cardiovascular effect of FR34235, a new dihydropyridine, with other calcium antagonists. J Cardiovasc Pharmacol 1983; 5:1074-1082.
17. Committee on the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals, NIH Publ no. 85-23. Washington, DC: NIH; 1985.
18. Nabika T, Nara Y, Ikeda K, Endo J, Yamori Y. Genetic heterogeneity of the spontaneously hypertensive rat. Hypertension 1991; 18:12-16.
19. American Veterinary Medical Association Panel on Euthanasia. Report of the AVMA Panel on Euthanasia. J Am Vet Med Assoc 1993, 202:229-249.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
21. Naruse M, Fujimaki Y, Naruse K, Yoshimoto T, Kawai M, Tanabe A, et al. Pathophysiological roles of endothelin in adrenal gland: a local modulator of aldosterone secretion. In: Maggi M, Baldi E (editors): Frontiers in endocrinology: endothelins in endocrinology, vol. 15. New York: Raven Press; 1995, pp. 241-253.
22. Uchida S, Takemoto F, Ogata E, Kurokawa K. Detection of endothelin-1 mRNA by RT-PCR in isolated rat renal tubules. Biochem Biophys Res Commun 1992; 188:108-113.
23. Seki T, Hagiwara H, Naruse K, Kadowaki M, Kashiwagi M, Demura H, et al. In situ identification of messenger RNA of endothelial type nitric oxide synthase in rat cardiac myocytes. Biochem Biophys Res Commun 1996; 218:601-605.
24. Seki T, Naruse M, Naruse K, Katafuchi T, Lodhi KM, Yoshimoto T, et al. Gene expression of endothelial type isoform of nitric oxide synthase in various tissues of stroke-prone spontaneously hypertensive rats. Hypertens Res 1997; 20:43-49.
25. Yoshimoto T, Naruse M, Naruse K, Fujimaki Y, Tanabe A, Muraki T, et al. Modulation of vascular natriuretic peptide receptor gene expression in hypertensive and obese hyperglycemic rats. Endocrinology 1995; 136:2427-2434.
26. Kaneko Y, Ikeda M, Ishii M. The clinical usefulness of FK235 in the long term treatment of essential hypertension. Ther Res 1986; 5:1157-1174.
27. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300.
28. Lariviere RL, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993; 21:916-920.
29. Day R, Lariviere R, Schiffrin EL. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 1995; 8:294-300.
30. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25 (part 2):769-773.
31. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney, one clip Goldblatt hypertension. J Hypertens 1996; 14:57-64.
32. Lariviere R, Sventek P, Schiffrin EL. Expression of endothelin-1 gene in blood vessels of adult spontaneously hypertensive rats. Life Sci 1995; 56:1889-1896.
33. Chou TC, Yen MH, Li CY, Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998; 31:643-648.
34. Flowers MA, Wang Y, Stewart RJ, Patel B, Marsden PA. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol 1995; 269:H1988-H1997.
35. Lüscher TF, Oemar BS, Boulanger CM, Hahn AW. Molecular and cellular biology of endothelin and its receptors: Part I. J Hypertens 1993; 11:7-11.
36. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 1995; 115:1377-1381.
37. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K. Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett 1993; 332:31-34.
38. McMahon EG, Palomo MA, Brown MA, Bertenshaw SR, Carter JS. Effects of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin recepter subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens 1993; 6:667-673.
39. A) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 1992; 20:940-948.
40. Douglas SE, Gellai M, Ezekiel M, Ohlstein EH. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different models of hypertension. J Hypertens 1994; 12:561-567.
41. Fogo A, Hellings SE, Inagami T, Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 1992; 42:770-774.
42. Firth JD, Raine AE, Ratcliffe J, Ledingham JG. Endothelin: an important factor in acute renal failure. Lancet 1988; 19:1179-1181.
43. Ohno A, Naruse M, Kato S, Hosaka M, Naruse K, Demura H, et al. Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats. J Hypertens 1992; 10:781-785.
44. Lüscher TF, Haefeli WE. L-Arginine in the clinical arena: tool or remedy? Circulation 1993; 26:653-658.
45. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992; 90:2092-2096.
46. Marsden PA, Heng HHQ, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268:17478-17488.
47. Hirosumi J, Nomoto A, Ohkubo Y, Sekiguchi C, Mutoh S, Yamaguchi I, et al. Inflammatory responses in cuff-induced atherosclerosis in rabbits. Atherosclerosis 1987; 64:243-254.
48. Nomoto A, Hirosumi J, Sekiguchi C, Mutoh S, Yamaguchi I, Aoki H. Antiatherogenic activity of FR34235 (nilvadipine), a new potent calcium antagonist: effect on cuff-induced intimal thickning of rabbit carotid artery. Atherosclerosis 1987; 64:255-261.
49. Yoshida H, Ayaori M, Suzukawa M, Hosoai H, Nishiwaki M, Ishikawa T, et al. Effects of Ca-antagonist on oxidative susceptibility of low density lipoprotein (LDL). Hypertension Res 1995; 18:47-53.